Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine☆
References (50)
- et al.
Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin
Lancet
(1978) - et al.
Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure
- et al.
Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes
Neurol Clin
(1992) Multiple system atrophy: clinical aspects, pathophysiology and treatment
Orthostatic hypotension
Med Clin North Am
(1989)- et al.
Management of chronic orthostatic hypotension
Am J Med
(1986) - et al.
The clinical spectrum of autonomic dysfunction
Am J Med
(1981) - et al.
Idiopathic onthostatic hypotension: a study of its natural history in 57 neurologically affected patients
Arch Neurol
(1970) - et al.
Midodrine: a new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome
Mayo Clin Proc
(1981) - et al.
Treatment of postural hypotension: a review
Drugs
(1990)
Mineralocorticoid-induced hypotension in patients with orthostatic hypotension
N Engl J Med
Pharmacological responses and biochemical changes in progressive autonomic failure
Treatment of chronic orthostatic hypotension with ergotamine
Circulation
Treatment of orthostatic hypotension with dihydroergotamine
BMJ
Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy
Clin Pharmacol Ther
Idiopathic postural hypotension: physiological observations and reports of a new mode of therapy
J Clin Invest
Effect of indomethacin inhibition of prostaglandin synthesis on blood pressure and plasma norepinephrine levels in patients with orthostatic hypotension
Neurology
Treatment of severe orthostatic hypotension by metoclopropamide
Ann Intern Med
Clonidine raises blood pressure in idiopathic orthostatic hypotension
Am J Med
Atrial tachypacing in the treatment of a patient with primary orthostatic hypotension
N Engl J Med
Orthostatic hypotension: II. Clinical diagnosis, testing, and treatment
Arch Intern Med
Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins
Eur J Clin Pharmacol
Effects of a-adrenoceptor agonists on cardiac output and blood pressure in spinally anesthetized ganglion-blocked dogs
Arch Int Pharmacodyn Ther
Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059
Arzneimittelforschung
Pharmacodynamics of midodrine, an antihypotensive agent
Clin Pharmacol Ther
Cited by (342)
Disease-modifying vs symptomatic treatments: Splitting over lumping
2023, Handbook of Clinical NeurologyMidodrine use in critically ill patients: a narrative review
2022, Critical Care and ResuscitationCardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
2022, Clinical TherapeuticsCitation Excerpt :A recent Cochrane review disappointingly found evidence that a benefit of fludrocortisone in reducing postural symptoms is uncertain.152 Midodrine is a vasopressor that increases standing blood pressure, thereby reducing orthostatic hypotension in two randomized controlled trials.153,154 The first double-blinded, randomized, placebo-controlled study (n = 97) found that midodrine at 10 mg 3 times daily for 4 weeks increased systolic blood pressure by a mean of 22 mm Hg (P < 0.001 vs placebo).154
Midodrine
2022, Primer on the Autonomic Nervous System, Fourth EditionPrinciples and Practice of Movement Disorders
2021, Principles and Practice of Movement Disorders
- ☆
This study was supported by a grant-in-aid from Roberts Pharmaceutical Corporation, Eatontown, New Jersey. This work was presented as an abstract at the 43rd Annual Meeting of the American Academy of Neurology, Boston, Massachusetts, April 21–27, 1991.